Smith Richard D, Thorsteinsdóttir Halla, Daar Abdallah S, Gold E Richard, Singers Peter A
Reader in Health Economics, Health Economics and Ethics Group, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, NR4 7TJ, England.
Bull World Health Organ. 2004 May;82(5):385-9.
Genomics, the comprehensive examination of an organism's entire set of genes and their interactions, will have a major impact on the way disease is diagnosed, prevented and treated in the new millennium. Despite the tremendous potential it holds for improving global health, genomics challenges policy-makers to ensure that its benefits are harnessed equitably across populations and nations. The classification of genomics as a global public good and the inequity encountered in the development and application of genomics knowledge are outlined in this paper, We examine the effect of the current patent system on the distribution of costs and benefits relating to genomics knowledge between countries of different economic strength. The global public goods concept provides a normative economic rationale for the modification of certain aspects of the current patent system and for the creation of complementary mechanisms to respond to the health needs of low-income and middle-income countries.
基因组学,即对生物体的全套基因及其相互作用进行全面检测,在新千年中将对疾病的诊断、预防和治疗方式产生重大影响。尽管基因组学在改善全球健康方面具有巨大潜力,但它也给政策制定者带来了挑战,即要确保其益处能在不同人群和国家间公平地得到利用。本文概述了将基因组学归类为全球公益物品以及在基因组学知识的开发和应用中所遇到的不公平现象。我们研究了现行专利制度对不同经济实力国家之间与基因组学知识相关的成本和收益分配的影响。全球公益物品概念为修改现行专利制度的某些方面以及创建补充机制以满足低收入和中等收入国家的健康需求提供了规范性经济依据。